Collegium Pharmaceutical (NASDAQ:COLL) Reaches New 52-Week High – Here’s What Happened

Collegium Pharmaceutical, Inc. (NASDAQ:COLL)’s share price hit a new 52-week high during mid-day trading on Thursday . The stock traded as high as $41.00 and last traded at $39.7150, with a volume of 55563 shares changing hands. The stock had previously closed at $35.85.

Wall Street Analysts Forecast Growth

A number of brokerages recently commented on COLL. Needham & Company LLC restated a “buy” rating and issued a $46.00 price target on shares of Collegium Pharmaceutical in a research report on Tuesday, October 28th. Wall Street Zen cut Collegium Pharmaceutical from a “strong-buy” rating to a “buy” rating in a research report on Saturday, October 18th. Zacks Research lowered Collegium Pharmaceutical from a “strong-buy” rating to a “hold” rating in a research note on Thursday, October 23rd. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Collegium Pharmaceutical in a research note on Wednesday, October 8th. Finally, HC Wainwright raised Collegium Pharmaceutical to a “strong-buy” rating and set a $44.00 price objective on the stock in a research note on Monday, August 11th. One analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating and three have given a Hold rating to the company. According to MarketBeat, Collegium Pharmaceutical has an average rating of “Moderate Buy” and an average target price of $42.33.

Collegium Pharmaceutical Stock Performance

The stock has a 50 day moving average of $35.59 and a 200 day moving average of $32.60. The company has a quick ratio of 1.10, a current ratio of 1.18 and a debt-to-equity ratio of 3.27. The company has a market capitalization of $1.26 billion, a price-to-earnings ratio of 38.50 and a beta of 0.61.

Collegium Pharmaceutical (NASDAQ:COLL) last issued its earnings results on Wednesday, September 4th. The specialty pharmaceutical company reported $1.26 earnings per share for the quarter. The business had revenue of $135.55 million during the quarter. Collegium Pharmaceutical had a return on equity of 97.28% and a net margin of 5.13%. As a group, analysts predict that Collegium Pharmaceutical, Inc. will post 5.62 EPS for the current year.

Insider Transactions at Collegium Pharmaceutical

In related news, EVP Thomas B. Smith sold 17,478 shares of the business’s stock in a transaction on Friday, August 29th. The stock was sold at an average price of $38.42, for a total transaction of $671,504.76. Following the sale, the executive vice president directly owned 70,264 shares in the company, valued at approximately $2,699,542.88. The trade was a 19.92% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director John Gordon Freund sold 11,659 shares of the company’s stock in a transaction dated Friday, August 8th. The stock was sold at an average price of $34.36, for a total value of $400,603.24. Following the completion of the transaction, the director owned 23,129 shares in the company, valued at $794,712.44. This represents a 33.51% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last three months, insiders have sold 55,792 shares of company stock worth $2,084,207. Insiders own 2.51% of the company’s stock.

Hedge Funds Weigh In On Collegium Pharmaceutical

Institutional investors have recently modified their holdings of the company. Rubric Capital Management LP boosted its holdings in Collegium Pharmaceutical by 5.3% in the second quarter. Rubric Capital Management LP now owns 3,157,743 shares of the specialty pharmaceutical company’s stock worth $93,374,000 after acquiring an additional 157,743 shares in the last quarter. Fuller & Thaler Asset Management Inc. boosted its holdings in Collegium Pharmaceutical by 1.4% in the first quarter. Fuller & Thaler Asset Management Inc. now owns 1,371,448 shares of the specialty pharmaceutical company’s stock worth $40,938,000 after acquiring an additional 19,568 shares in the last quarter. Emerald Advisers LLC raised its stake in shares of Collegium Pharmaceutical by 1.3% in the second quarter. Emerald Advisers LLC now owns 837,549 shares of the specialty pharmaceutical company’s stock worth $24,766,000 after purchasing an additional 11,074 shares during the last quarter. Geode Capital Management LLC raised its stake in shares of Collegium Pharmaceutical by 1.9% in the second quarter. Geode Capital Management LLC now owns 780,243 shares of the specialty pharmaceutical company’s stock worth $23,075,000 after purchasing an additional 14,709 shares during the last quarter. Finally, Massachusetts Financial Services Co. MA raised its stake in shares of Collegium Pharmaceutical by 18.1% in the first quarter. Massachusetts Financial Services Co. MA now owns 713,854 shares of the specialty pharmaceutical company’s stock worth $21,309,000 after purchasing an additional 109,655 shares during the last quarter.

About Collegium Pharmaceutical

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.